Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
Li‐Tzong Chen, Do‐Youn Oh, Min‐Hee Ryu, et al.
Cancer Research and Treatment (2017) Vol. 49, Iss. 4, pp. 851-868
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Dimakatso Alice Senthebane, Arielle Rowe, Nicholas Ekow Thomford, et al.
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 7, pp. 1586-1586
Open Access | Times Cited: 369
VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer
Lian Lian, Xiangli Li, Mengdan Xu, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 117
Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
Henrik Nienhüser, Thomas Schmidt
International Journal of Molecular Sciences (2017) Vol. 19, Iss. 1, pp. 43-43
Open Access | Times Cited: 95
Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
Hardeep Singh Tuli, Ajay Kumar, Seema Ramniwas, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7653-7653
Open Access | Times Cited: 43
Third- and later-line treatment in advanced or metastatic gastric cancer: a systematic review and meta-analysis
Alessandro Rizzo, Veronica Mollica, Angela Dalia Ricci, et al.
Future Oncology (2019) Vol. 16, Iss. 2, pp. 4409-4418
Closed Access | Times Cited: 73
Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients?
Hong Sun, Tao Li, Rongyuan Zhuang, et al.
Medicine (2017) Vol. 96, Iss. 13, pp. e6394-e6394
Open Access | Times Cited: 72
Ononin: A comprehensive review of anticancer potential of natural isoflavone glycoside
Ujjawal Sharma, Bunty Sharma, Ambrish Mishra, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 6
Closed Access | Times Cited: 7
GSE1 predicts poor survival outcome in gastric cancer patients by SLC7A5 enhancement of tumor growth and metastasis
Keshuo Ding, Sheng Tan, Xing Huang, et al.
Journal of Biological Chemistry (2018) Vol. 293, Iss. 11, pp. 3949-3964
Open Access | Times Cited: 50
Tumor progression-dependent angiogenesis in gastric cancer and its potential application
Hsi‐Lung Hsieh, Ming-Ming Tsai
World Journal of Gastrointestinal Oncology (2019) Vol. 11, Iss. 9, pp. 686-704
Open Access | Times Cited: 50
Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT
Xing Kang, En Xu, Xingzhou Wang, et al.
Cell Death and Disease (2021) Vol. 12, Iss. 10
Open Access | Times Cited: 41
Nanoparticles designed to regulate tumor microenvironment for cancer therapy
Min Li, Fangrong Zhang, Yujie Su, et al.
Life Sciences (2018) Vol. 201, pp. 37-44
Closed Access | Times Cited: 45
Prognostic value of a novel FPR biomarker in patients with surgical stage II and III gastric cancer
Jing Zhang, Shuqi Li, Zhihua Liao, et al.
Oncotarget (2017) Vol. 8, Iss. 43, pp. 75195-75205
Open Access | Times Cited: 41
Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review
Fariba Peytam, Zahra Emamgholipour, Ali Mousavi, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106831-106831
Closed Access | Times Cited: 13
Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
Yong Zhang, Chun Han, Juan Li, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 38
Antiangiogenic effects of oridonin
Lili Tian, Kangjie Xie, Donglai Sheng, et al.
BMC Complementary and Alternative Medicine (2017) Vol. 17, Iss. 1
Open Access | Times Cited: 37
Deciphering the anticancer potential of thymoquinone: in-depth exploration of the potent flavonoid from Nigella sativa
Bunty Sharma, Himanshu Shekhar, Anidrisha Sahu, et al.
Molecular Biology Reports (2025) Vol. 52, Iss. 1
Closed Access
Gastric cancer vaccines synthesized using a TLR7 agonist and their synergistic antitumor effects with 5-fluorouracil
Xiaodong Wang, Yu Liu, Yuwen Diao, et al.
Journal of Translational Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 28
Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies
Letizia Procaccio, Vera Damuzzo, Francesca Di Sarra, et al.
Drug Safety (2019) Vol. 42, Iss. 2, pp. 159-179
Closed Access | Times Cited: 26
Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
Masatoshi Kudo, Takuji Okusaka, Kenta Motomura, et al.
Journal of Gastroenterology (2020) Vol. 55, Iss. 6, pp. 627-639
Open Access | Times Cited: 26
Pull the plug: Anti‐angiogenesis potential of natural products in gastrointestinal cancer therapy
Yanling Ai, Ziyi Zhao, Hengyi Wang, et al.
Phytotherapy Research (2022) Vol. 36, Iss. 9, pp. 3371-3393
Closed Access | Times Cited: 16
Dihydroartemisinin inhibited vasculogenic mimicry in gastric cancer through the FGF2/FGFR1 signaling pathway
Huina Wang, Qingzhu Ding, Haihua Zhou, et al.
Phytomedicine (2024) Vol. 134, pp. 155962-155962
Open Access | Times Cited: 3
Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
Min‐Hee Ryu, Kyung Hee Lee, Lin Shen, et al.
Cancer Medicine (2022) Vol. 12, Iss. 7, pp. 7784-7794
Open Access | Times Cited: 14
<p>Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the <em>KDR</em> Gene Polymorphism</p>
Zizheng Song, Lifen Zhao, Jing Zuo, et al.
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 603-613
Open Access | Times Cited: 20
Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer
Linyan Zhang, Simeng Qin, Liuyi Lu, et al.
The International Journal of Biological Markers (2022) Vol. 37, Iss. 1, pp. 66-73
Open Access | Times Cited: 12
Regorafenib inhibited gastric cancer cells growth and invasion via CXCR4 activated Wnt pathway
Xiaolin Lin, Qi Xu, Lei Tang, et al.
PLoS ONE (2017) Vol. 12, Iss. 5, pp. e0177335-e0177335
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top